BioLineRx licenses inflammation treatment
By JERUSALEM POST BUSINESS STAFF
March 22, 2007 06:53
BioLineRx Ltd., said Wednesday it signed a worldwide exclusive license agreement with Yissum Research Development Co. of Hebrew University and Ramot at Tel Aviv University Ltd., the technology transfer company of TAU, for the development and commercialization of BL-4020, a novel peptide for the treatment of inflammatory diseases.
Financial terms of the license were not disclosed.